INVEX THERAPEUTICS LTDINVEX THERAPEUTICS LTDINVEX THERAPEUTICS LTD

INVEX THERAPEUTICS LTD

No trades
See on Supercharts

IXC fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses on understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
IXC has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company